Palavras-chave
antiplaquetário
revascularização de membros inferiores
doença arterial periférica
Como Citar
Resumo
Este artigo tem por objetivo realizar uma varredura da literatura médica vigente sobre o uso de Rivaroxabana em pacientes com doença arterial periférica submetidos a revascularização. Foram utilizados como motores de busca os indexadores MEDLINE (PubMed) e Excerpta Medica Database (Embase) para seleção dos artigos, através dos unitermos “Rivaroxaban, Atrial Lower Limb Revascularization’’. Conclui-se que a terapia com Rivaroxabana se mostrou eficaz, apresentando evidência mais forte de redução de evento como infarto agudo do miocárdio, acidente vascular cerebral isquêmico, morte cardiovascular, trombose a curto e longo prazo.
Referências
BONACA, M. P. et al. Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD. Clinical cardiology, v. 45, n. 12, p. 1143–1146, 2022.
BONACA, M. P. et al. Consistent benefit of rivaroxaban early and late after lower extremity revascularization. Journal of the American College of Cardiology, v. 81, n. 8, p. 2015, 2023.
DEBUS, E. S. et al. Effect of rivaroxaban and aspirin in patients with peripheral artery disease undergoing surgical revascularization: Insights from the VOYAGER PAD trial. Circulation, v. 144, n. 14, p. 1104–1116, 2021.
FERREIRA, V. et al. Effectiveness and safety of rivaroxaban compared to acenocumarol after infrainguinal surgical revascularization. Annals of vascular surgery, v. 55, p. 78–84, 2019.
HESS, C. N. et al. Rivaroxaban and risk of venous thromboembolism in patients with symptomatic peripheral artery disease after lower extremity revascularization. JAMA network open, v. 5, n. 6, p. e2215580, 2022.
JI, Y. et al. Comparison of rivaroxaban-based dual antithrombotic and antiplatelet therapies for symptomatic patients with lower-extremity peripheral artery disease post-revascularization: a retrospective cohort study. Therapeutic advances in chronic disease, v. 14, p. 20406223231213262, 2023.
PELICON, K. et al. Effectiveness and safety of anticoagulant versus antiplatelet therapy in patients after endovascular revascularisation of the lower limb. Slovenian Medical Journal, 2022.
SOEGAARD, M. et al. Applicability of the VOYAGER trial criteria: a cohort study on patients in the nationwide Danish Vascular Registry. European heart journal, v. 41, n. Supplement_2, 2020.
WEISSLER, E. H. et al. The role for combined antithrombotic therapy with platelet and coagulation inhibition after lower extremity revascularization. JACC. Cardiovascular interventions, v. 14, n. 7, p. 796–802, 2021.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Mari Edeline veras Dourado, Gabriela Paz Mendes de Lima, Sabrinny Viana Franklin , Kílvia Mairla Gonçalves Trigueiro, Ellen da Costa Araújo , Dávila Ruama Sousa Silva , Sammyra Bárbara Maia Lima , Maximmus Maia Lima, Paulo Afonso Neiva Cavalcante , Isaque Soares Lima, Giovana Corrêa de Moraes Nardo, Carolina Monteiro Scandiuzzi, Bárbara Alessandra Solano Silva, Thyago Layron Sampaio de Abreu, Ane Kassia de Carvalho Barbosa , Isabella Bueno Pereira da Rocha , Raquel Araújo Nogueira